Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. Impact of human epidermal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results